Which should you choose? Here's what you need to know.
Mazdutide actually beat semaglutide in a head-to-head trial by adding a glucagon receptor component. But semaglutide is FDA-approved with far more real-world data.
Mazdutide is a GLP-1/glucagon dual agonist that outperformed semaglutide in the head-to-head DREAMS-3 trial — 48% of patients hit both blood sugar and weight loss targets vs 21% on semaglutide.
Choose Mazdutide if:
You want a dual agonist that showed superiority over semaglutide in trials, and you have access to it through international channels.
Semaglutide is the most widely used GLP-1 agonist worldwide with FDA approval, years of safety data, and proven cardiovascular benefits in the SELECT trial.
Choose Semaglutide if:
You want the most proven, widely available, FDA-approved option with the longest safety track record.
Once you've decided which peptide fits your needs, here's how they compare on price and vendor options.
Our top-rated vendor for each, based on trust scores, purity testing, and price.
We re-check vendor prices continuously and score vendors on Finnrick blind-test results — samples bought anonymously and sent to a lab, not vendor claims. No vendor can pay to rank higher. See our full methodology.